Withdrawal of rofecoxib - a wake up call for drug safety

Kathmandu Univ Med J (KUMJ). 2004 Oct-Dec;2(4):360.
No abstract available

MeSH terms

  • Cyclooxygenase 2 Inhibitors / adverse effects*
  • Drug Approval*
  • Humans
  • Lactones / adverse effects*
  • Nepal
  • Safety
  • Sulfones / adverse effects*
  • United States
  • United States Food and Drug Administration

Substances

  • Cyclooxygenase 2 Inhibitors
  • Lactones
  • Sulfones
  • rofecoxib